Identifying an obinutuzumab resistant subpopulation of monocyte-derived-macrophages from patients with CLL.
- Resource Type
- Letter
- Authors
- Burgess, Melinda; Chen, Yu Chen Enya; Mapp, Sally; Mollee, Peter; Gill, Devinder; Saunders, Nicholas A.
- Source
- Leukemia & Lymphoma. Nov2020, Vol. 61 Issue 11, p2738-2742. 5p.
- Subject
- *CHRONIC lymphocytic leukemia
*LYMPHOCYTIC leukemia
*ANTIBODY-dependent cell cytotoxicity
*CHRONIC leukemia
*PATTERN perception receptors
- Language
- ISSN
- 1042-8194
Antibody therapies are important treatment options for Chronic lymphocytic leukemia (CLL). Paradoxically, MDMs also play a critical role in tumor cell killing either through a) recognition and phagocytosis of tumor cells mediated I via i pattern recognition receptors [[6]] or b) Fc R-dependent phagocytosis of tumor cells that have been opsonized with a therapeutic antibody (e.g. obinituzumab) [[7]]. Given the evidence that macrophages are key effector cells that clear opsonized CLL cells [[9]] it is surprising that little attention has focused on characterizing the phenotype of the MDMs responsible. [Extracted from the article]